Voyager Therapeutics, Inc. (VYGR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Voyager Therapeutics, Inc. (VYGR) Healthcare & Pipeline Overview

Voyager Therapeutics, Inc., a gene therapy company, is focused on developing innovative treatments for severe neurological diseases. With a lead clinical candidate targeting Parkinson's disease and preclinical programs addressing ALS and Huntington's, Voyager leverages strategic collaborations to advance its adeno-associated virus (AAV) gene therapy platform.

What Is the Investment Thesis for VYGR?

Voyager Therapeutics presents a notable research candidate within the gene therapy space, driven by its innovative AAV platform and focus on neurological diseases. The company's lead clinical candidate, VY-AADC, targeting Parkinson's disease, offers potential for significant clinical impact. Positive Phase 1 trial results could serve as a major catalyst. Preclinical programs targeting ALS, Huntington's, and other neurodegenerative diseases provide further upside potential. Strategic collaborations with Neurocrine, Pfizer, and Novartis validate Voyager's technology and provide financial support. However, the company's negative profit margin of -319.6% highlights the high R&D costs and inherent risks associated with biotechnology. Successful clinical trials and regulatory approvals are critical for future growth and profitability.

Based on FMP financials and quantitative analysis

VYGR Key Highlights

Market capitalization of $201M reflects investor valuation of Voyager's pipeline and gene therapy platform.

• Gross margin of 97.4% indicates strong potential profitability upon commercialization of successful therapies.
• Profit margin of -319.6% highlights the significant R&D investment required in the biotechnology sector.
• Lead clinical candidate VY-AADC is in open-label Phase 1 clinical trial for Parkinson's disease, a large and underserved market.
• Strategic collaborations with Neurocrine Biosciences, Pfizer Inc., and Novartis Pharma, A.G. provide financial resources and validation of Voyager's technology.

Who Are VYGR's Competitors?

VYGR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VYGR's Key Strengths?

Proprietary AAV gene therapy platform.

• Strong intellectual property portfolio.
• Strategic collaborations with leading pharmaceutical companies.
• Focus on neurological diseases with high unmet medical needs.

What Are VYGR's Weaknesses?

High R&D costs and long development timelines.

• Reliance on clinical trial success and regulatory approvals.
• Negative profit margin.
• Limited commercialization experience.

What Could Drive VYGR Stock Higher?

Data readout from the Phase 1 clinical trial of VY-AADC for Parkinson's disease.

• Advancement of preclinical programs targeting ALS, Huntington's disease, and Friedreich's ataxia.
• Potential for new strategic collaborations with pharmaceutical companies.
• Development of next-generation AAV vectors with improved tropism and transduction efficiency.

What Are the Key Risks for VYGR?

Financial-distress signal — its Altman Z-Score of -1.64 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-57.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures could delay or halt the development of Voyager's gene therapies.
• Regulatory setbacks could prevent the approval and commercialization of Voyager's products.
• Competition from other gene therapy companies could limit Voyager's market share.
• Patent challenges could threaten Voyager's intellectual property rights.
• High R&D costs could strain Voyager's financial resources.

What Are the Growth Opportunities for VYGR?

• Expansion of VY-AADC into later-stage clinical trials for Parkinson's disease represents a significant growth opportunity. Positive results from Phase 2 and Phase 3 trials could lead to regulatory approval and commercialization, addressing a large market with unmet needs.
• Advancement of preclinical programs targeting ALS, Huntington's disease, and Friedreich's ataxia offers long-term growth potential. These programs address rare and devastating neurological disorders with limited treatment options. Successful development and commercialization of these therapies could generate significant revenue and establish Voyager as a leader in gene therapy for rare diseases.
• Leveraging the AAV gene therapy platform to develop treatments for additional neurological indications represents a key growth opportunity. Voyager can expand its pipeline by targeting new diseases and developing novel gene therapies. This platform approach allows for efficient development and scalability, enhancing Voyager's long-term growth prospects.
• Strategic collaborations with pharmaceutical companies provide access to funding, expertise, and commercialization capabilities. Voyager can continue to pursue partnerships with leading companies to accelerate the development and commercialization of its gene therapy programs. These collaborations can generate upfront payments, milestone payments, and royalties, providing significant financial resources.
• Development of next-generation AAV vectors with improved tropism and transduction efficiency can enhance the efficacy and safety of Voyager's gene therapies. Investing in research and development to improve its AAV platform can provide a competitive advantage and enable Voyager to target a wider range of neurological diseases. This innovation can lead to more effective treatments and greater market penetration.

What Are VYGR's Competitive Advantages?

• Proprietary AAV gene therapy platform provides a competitive advantage in developing novel therapies.
• Strong intellectual property portfolio protects their AAV vectors and therapeutic candidates.
• Strategic collaborations with leading pharmaceutical companies provide access to funding and expertise.
• Focus on neurological diseases with high unmet medical needs creates a niche market with limited competition.

What Does VYGR Do?

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. Incorporated in 2013 and headquartered in Cambridge, Massachusetts, Voyager is pioneering the application of adeno-associated virus (AAV) gene therapy to address diseases with significant unmet medical needs. The company's approach involves delivering therapeutic genes directly into the central nervous system to address the underlying causes of neurological disorders. Voyager's lead clinical candidate, VY-AADC, is currently in an open-label Phase 1 clinical trial for the treatment of Parkinson's disease. This therapy aims to improve motor function by delivering the AADC gene directly into the brain, enabling patients to produce dopamine. Beyond Parkinson's disease, Voyager has a robust pipeline of preclinical programs targeting other devastating neurological conditions, including VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, VY-FXN01 for Friedreich's ataxia, and a Tau program focused on tauopathies such as Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as spinal muscular atrophy. Voyager has established strategic collaborations with leading pharmaceutical companies, including Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G., to advance the research, development, and commercialization of its AAV gene therapy products. These collaborations provide Voyager with financial resources and expertise to accelerate the development of its pipeline and expand its platform technologies.

What Products and Services Does VYGR Offer?

• Develop gene therapies for severe neurological diseases.
• Utilize adeno-associated virus (AAV) vectors to deliver therapeutic genes.
• Focus on diseases with significant unmet medical needs, such as Parkinson's disease and ALS.
• Conduct preclinical and clinical trials to evaluate the safety and efficacy of their gene therapies.
• Collaborate with pharmaceutical companies to advance the development and commercialization of their products.
• Pioneer innovative approaches to address the underlying causes of neurological disorders.

How Does VYGR Make Money?

• Develop and out-license gene therapy programs to larger pharmaceutical companies.
• Generate revenue through collaboration agreements, including upfront payments, milestone payments, and royalties.
• Focus on early-stage research and development, partnering with larger companies for late-stage clinical trials and commercialization.
• Maintain intellectual property rights to their AAV gene therapy platform and therapeutic candidates.

What Industry Does VYGR Operate In?

Voyager Therapeutics operates in the rapidly evolving biotechnology industry, specifically within the gene therapy market. The gene therapy market is projected to experience substantial growth, driven by advancements in vector technology and increasing success in clinical trials. Voyager's focus on AAV gene therapy positions it within a competitive landscape that includes companies like Biogen and Sarepta Therapeutics, which are also developing gene therapies for neurological disorders. Strategic collaborations and platform innovation are key to success in this industry.

Who Are VYGR's Key Customers?

• Patients suffering from severe neurological diseases, such as Parkinson's disease, ALS, and Huntington's disease.
• Pharmaceutical companies seeking to expand their portfolios of neurological therapies.
• Healthcare providers who prescribe and administer gene therapies to patients.

Wall Street analysts project Voyager Therapeutics, Inc. revenue of about $41.2M for fiscal 2026, with EPS near $-1.66. The estimate reflects 8 contributing analysts.

Voyager Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2.2% below estimates on average.

Voyager Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.64 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Voyager Therapeutics, Inc. stands at -57.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -54.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -61.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.51 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -54.1%, the inverse of the P/E and a quick read on earnings relative to price.

Voyager Therapeutics, Inc. (VYGR) Valuation Context

Valued at $201M, VYGR is classified as a micro-cap stock. Relative to its peer group, VYGR's quantitative score of 11/100 is below the peer average of 78/100.

VYGR Revenue & Earnings Trend

In Q2 2026, VYGR generated $3.2M in top-line revenue, marking a sequential increase of 22.1%. The company recorded a net loss of $24.5M, with diluted EPS of $-0.40. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, VYGR averaged $-0.45 in diluted EPS.

Company Profile

Voyager Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lexington, US. The company is led by CEO Alfred W. Sandrock Jr.. VYGR has traded publicly since 2015.

VYGR Financials

VYGR Latest News

VYGR Analyst Consensus

VYGR MoonshotScore

Common Questions About VYGR (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources